Bionano Genomics, Inc. (BNGO) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report on Form 10-Q for Bionano Genomics, Inc. for the period ended June 30, 2026. The Company provides optical genome mapping (OGM) solutions, diagnostic services, and software. As of the reporting date, the Company had an installed base of 397 OGM systems. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $8.17 million | $14.86 million |
| Net Loss | $(7.42) million | $(15.73) million |
| Loss Per Share (Basic & Diluted) | $(0.64) | $(1.40) |
| Gross Margin (Total) | 53% | 51% |
| Cash and Cash Equivalents | $3.73 million (as of June 30, 2026) | |
| Short-Term Investments | $6.19 million (as of June 30, 2026) | |
| Working Capital | $14.84 million (as of June 30, 2026) | |
| Convertible Debentures Outstanding | $0 (Fully redeemed in May 2026) | |
| Accumulated Deficit | $(735.35) million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 21% year-over-year for the quarter and 13% for the six-month period. This was driven by a 46% increase in instrument revenue and a 31% increase in consumable revenue (flowcells sold increased 27% QoQ). Software revenue declined 16% for the quarter.
- Expense Management: Operating expenses remained relatively flat year-over-year for the quarter (+2%) and six-month period (+0%). SG&A expenses decreased 5% for the six-month period due to reduced professional fees and stock-based compensation, partially offset by executive transition costs.
- Debt Repayment: The Company fully redeemed the outstanding principal balance of $10.3 million under its JGB Convertible Debentures in May 2026, shortly after maturity. Consequently, no convertible debt is outstanding as of June 30, 2026.
- Geographic Shift: EMEA revenue share increased to 59.2% of total revenue for the quarter, while Americas share decreased to 37.0%. Asia Pacific revenue declined significantly to 3.8% due to regional headwinds.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. The Company expects to continue incurring operating losses and negative cash flows. Current cash and investments are insufficient to fund operations beyond the first quarter of 2027 without additional financing.
- Capital Needs: The Company is actively evaluating debt and equity financing sources. If additional capital cannot be raised in the near term, the Company may need to curtail operations or seek bankruptcy protection.
- Operational Headwinds: The Company faces supply chain constraints, specifically regarding computing components (memory), which may lead to cost pressures. Growth in the Asia Pacific region has slowed due to geopolitical and macroeconomic factors.
- Strategic Actions: The Board maintains a strategy committee to evaluate options to maximize stakeholder value, including potential debt/equity financing, combinations with other companies, or asset sales.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing agreements, given the explicit "substantial doubt" regarding the going concern status.
- Debt Status: Confirm the full redemption of the JGB Debentures and check for any new debt covenants or financing arrangements disclosed in subsequent filings.
- Revenue Mix: Monitor the sustainability of the shift toward EMEA revenue and the decline in software revenue, which may impact long-term recurring revenue models.
- Supply Chain Costs: Assess the impact of rising computing component costs on future gross margins, particularly for instrument sales.
- Equity Dilution: Review the Company's At-The-Market (ATM) facility with Wainwright and potential future equity issuances required to fund operations.